BioCryst Pharma (BCRX) Misses Q1 EPS by 303c ; Offers Guidance
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.68 -0.23%
EPS Growth %: -43.8%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: -43.8%
Financial Fact:
Total revenues: 7.76M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($2.98), $3.03 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $156.41 million versus the consensus estimate of $151.66 million.
GUIDANCE:
BioCryst Pharma sees FY2026 revenue of $635-660 million, versus the consensus of $650.2 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- U.S. and Denmark close in on a Greenland deal - Reuters
- SmartKem (SMTK) files for 15.13M share offering by selling stockholders
- InMed Pharmaceuticals gets Nasdaq equity deficiency notice
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
